medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2016-11-62-66medsovet-1543Research ArticleДЕМИЕЛИНИЗИРУЮЩИЕ ЗАБОЛЕВАНИЯDEMYELINATING DISEASESПРОБЛЕМЫ ТАКТИКИ ВЕДЕНИЯ ПАЦИЕНТОК С РАССЕЯННЫМ СКЛЕРОЗОМ ФЕРТИЛЬНОГО ВОЗРАСТАTREATMENT PROBLEMS OF PATIENTS WITH MULTIPLE SCLEROSIS OF CHILDBEARING AGEПОПОВАЕ. В.POPOVAE. V.

к.м.н.

ШАРАНОВАС. Н.SHARANOVAS. N.БОЙКОА. Н.BOYKOA. N.

д.м.н. профессор

Межокружное отделение рассеянного склероза на базе Городской клинической больницы №24 Департамента здравоохранения г. Москвы; Российский национальный исследовательский медицинский университет им. Н.И. Пирогова, МоскваРоссияMoscow inter-area branch of the Multiple Sclerosis (City Clinical Hospital №24); Department of Neurology, Neurosurgery and Medical Genetics Rnrmu them. NI PirogovRussian FederationМежокружное отделение рассеянного склероза на базе Городской клинической больницы №24 Департамента здравоохранения г. Москвы;РоссияMoscow inter-area branch of the Multiple Sclerosis (City Clinical Hospital №24);Russian Federation2016301220160116266Copyright © ПОПОВА Е.В., ШАРАНОВА С.Н., БОЙКО А.Н., 20162016ПОПОВА Е.В., ШАРАНОВА С.Н., БОЙКО А.Н.POPOVA E.V., SHARANOVA S.N., BOYKO A.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1543

За последние 20 лет появился целый ряд препаратов, изменяющих течение рассеянного склероза. Однако единого алгоритма ведения пациенток фертильного возраста так и не выработано. С учетом появления новых препаратов с большей эффективностью, но в то же время и с большими рисками патологического воздействия на плод необходимо более детально представлять алгоритм ведения данной категории больных.

There was a whole series of drugs that change the course of multiple sclerosis over the past 20 years. However, a single algorithm of patients of childbearing age has yet been developed. There are new drugs more efficiently, but at the same time with high risk of pathological effects on the fetus, which requires more detail to provide algorithm of this category of patients.

рассеянный склерозфертильностьmultiple sclerosisfertilityReferencesVukusic S. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of postpartum relapse. Brain, 2004, 127(6): 1353-1360.Vukusic S. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of postpartum relapse. Brain, 2004, 127(6): 1353-1360.Addis A, Sharabi S and Bonati M. (). Risk Classification Systems for Drug Use During Pregnancy. Drug Safety, 2000, 23(3): 245-253.Addis A, Sharabi S and Bonati M. (). Risk Classification Systems for Drug Use During Pregnancy. Drug Safety, 2000, 23(3): 245-253.Ng P, Lam C, Lee C, Fok T, Chan I, Ma K and Wong E. Changes in serum leptin concentration after corticosteroid treatment in preterm infants. Acta Paediatrica, 2007, 91(6): 684-690.Ng P, Lam C, Lee C, Fok T, Chan I, Ma K and Wong E. Changes in serum leptin concentration after corticosteroid treatment in preterm infants. Acta Paediatrica, 2007, 91(6): 684-690.Houtchens M and Kolb C. Multiple sclerosis and pregnancy: therapeutic considerations. Journal of Neurology, 2012, 260(5): 1202-1214.Houtchens M and Kolb C. Multiple sclerosis and pregnancy: therapeutic considerations. Journal of Neurology, 2012, 260(5): 1202-1214.Ghezzi A, Annovazzi P, Portaccio E, Cesari E and Amato M. Current recommendations for multiple sclerosis treatment in pregnancy and puerperium. Expert Review of Clinical Immunology, 2013, 9(7): 683-692.Ghezzi A, Annovazzi P, Portaccio E, Cesari E and Amato M. Current recommendations for multiple sclerosis treatment in pregnancy and puerperium. Expert Review of Clinical Immunology, 2013, 9(7): 683-692.Fox R, Miller D Phillips, J, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser M, Viglietta V and Dawson K. Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis. New England Journal of Medicine, 2012, 367(12): 1087-1097.Fox R, Miller D Phillips, J, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser M, Viglietta V and Dawson K. Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis. New England Journal of Medicine, 2012, 367(12): 1087-1097.Fragoso Y. Glatiramer acetate to treat multiple sclerosis during pregnancy and lactation: a safety evaluation. Expert Opinion on Drug Safety, 2014, 13(12): 1743-1748.Fragoso Y. Glatiramer acetate to treat multiple sclerosis during pregnancy and lactation: a safety evaluation. Expert Opinion on Drug Safety, 2014, 13(12): 1743-1748.Cassina M, Johnson D, Robinson L, Braddock S, Xu R, Jimenez J, Mirrasoul N, Salas E, Luo Y, Jones K and Chambers C. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis & Rheumatism, 2012, 64(7): 2085-2094.Cassina M, Johnson D, Robinson L, Braddock S, Xu R, Jimenez J, Mirrasoul N, Salas E, Luo Y, Jones K and Chambers C. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis & Rheumatism, 2012, 64(7): 2085-2094.Warnke C, Stüve O and Kieseier B. Teriflunomide for the treatment of multiple sclerosis. Clinical Neurology and Neurosurgery, 2013, 115: S90-S94.Warnke C, Stüve O and Kieseier B. Teriflunomide for the treatment of multiple sclerosis. Clinical Neurology and Neurosurgery, 2013, 115: S90-S94.Litjens N, Burggraaf J, van Strijen E, van Gulpen C, Mattie H, Schoemaker R, van Dissel J, Thio H and Nibbering P. Pharmacokinetics of oral fumarates in healthy subjects. British Journal of Clinical Pharmacology, 2004, 58(4): 429-432.Litjens N, Burggraaf J, van Strijen E, van Gulpen C, Mattie H, Schoemaker R, van Dissel J, Thio H and Nibbering P. Pharmacokinetics of oral fumarates in healthy subjects. British Journal of Clinical Pharmacology, 2004, 58(4): 429-432.Fox R, Miller D, Phillips J et al. PlaceboControlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis. New England Journal of Medicine, 2012, 367(12): 1087-1097. doi:10.1056/nejmoa1206328.Fox R, Miller D, Phillips J et al. PlaceboControlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis. New England Journal of Medicine, 2012, 367(12): 1087-1097. doi:10.1056/nejmoa1206328.Gold R, Phillips J, Havrdova E, Bar-Or A, Kappos L, Kim N, Thullen T, Valencia P, Oliva L, Novas M, Li J, Sweetser M, Kurukulasuriya N, Viglietta V and Fox R. Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience. Neurology and Therapy, 2015, 4(2): 93-104.Gold R, Phillips J, Havrdova E, Bar-Or A, Kappos L, Kim N, Thullen T, Valencia P, Oliva L, Novas M, Li J, Sweetser M, Kurukulasuriya N, Viglietta V and Fox R. Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience. Neurology and Therapy, 2015, 4(2): 93-104.Geissbuhler Y, Butzkueven H, Hernandez-Diaz S, Koren G, MacDonald T, Tilson H, Starzyk K, Plana E, Cremer M von Rosenstiel P and Hellwig K. Multinational Gilenya (Fingolimod) Pregnancy Exposure Registry in Multiple Sclerosis: Study Design (P06.189).Neurology, 2012, 78(Meeting Abstracts 1): P06.189-P06.189.Geissbuhler Y, Butzkueven H, Hernandez-Diaz S, Koren G, MacDonald T, Tilson H, Starzyk K, Plana E, Cremer M von Rosenstiel P and Hellwig K. Multinational Gilenya (Fingolimod) Pregnancy Exposure Registry in Multiple Sclerosis: Study Design (P06.189).Neurology, 2012, 78(Meeting Abstracts 1): P06.189-P06.189.Karlsson G, Francis G, Koren G, Heining P, Zhang X, Cohen J, Kappos L and Collins W. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology, 2014, 82(8): 674-680.Karlsson G, Francis G, Koren G, Heining P, Zhang X, Cohen J, Kappos L and Collins W. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology, 2014, 82(8): 674-680.Alroughani R, Alroughani R, Almulla A, Lamdhade S and Thussu A. (). Severe reactivation of multiple sclerosis after discontinuation of fingolimod: An IRIS-associated phenomenon. Multiple Sclerosis and Related Disorders, 2014, 3(6): 748.Alroughani R, Alroughani R, Almulla A, Lamdhade S and Thussu A. (). Severe reactivation of multiple sclerosis after discontinuation of fingolimod: An IRIS-associated phenomenon. Multiple Sclerosis and Related Disorders, 2014, 3(6): 748.Hartung H, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey S, Krapf H and Zwingers T. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. The Lancet, 2002, 360(9350): 2018-2025.Hartung H, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey S, Krapf H and Zwingers T. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. The Lancet, 2002, 360(9350): 2018-2025.De Santis M, Straface G, Cavaliere A, Rosati P, Batocchi A and Caruso A. The first case of mitoxantrone exposure in early pregnancy. NeuroToxicology, 2007, 28(3): 696-697.De Santis M, Straface G, Cavaliere A, Rosati P, Batocchi A and Caruso A. The first case of mitoxantrone exposure in early pregnancy. NeuroToxicology, 2007, 28(3): 696-697.Hellwig K, Schimrigk S, Chan A, Epplen J and Gold R. (). A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis. Journal of the Neurological Sciences, 2011, 307(1-2): 164-165.Hellwig K, Schimrigk S, Chan A, Epplen J and Gold R. (). A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis. Journal of the Neurological Sciences, 2011, 307(1-2): 164-165.Schneider H, Weber C, Hellwig K, Schroten H and Tenenbaum T. Natalizumab treatment during pregnancy – effects on the neonatal immune system. Acta Neurologica Scandinavica, 2012, 127(1): e1-e4.Schneider H, Weber C, Hellwig K, Schroten H and Tenenbaum T. Natalizumab treatment during pregnancy – effects on the neonatal immune system. Acta Neurologica Scandinavica, 2012, 127(1): e1-e4.Taylor L, Varghese S, Hogge G, Bloomgren G, Cristiano L, Bozic C, Kooijmans M and Quinn G. Mo1050 Natalizumab use in Patients With Crohn’s Disease and Relapsing Multiple Sclerosis: Updated Utilization and Safety Results From the Touch(r) Prescribing Program, the Pregnancy Registry, and the INFORM and TYGRIS Studies. Gastroenterology, 2012, 142(5): 581-58.Taylor L, Varghese S, Hogge G, Bloomgren G, Cristiano L, Bozic C, Kooijmans M and Quinn G. Mo1050 Natalizumab use in Patients With Crohn’s Disease and Relapsing Multiple Sclerosis: Updated Utilization and Safety Results From the Touch(r) Prescribing Program, the Pregnancy Registry, and the INFORM and TYGRIS Studies. Gastroenterology, 2012, 142(5): 581-58.Fagius J and Burman J. (). Normal outcome of pregnancy with ongoing treatment with natalizumab. Acta Neurologica Scandinavica, 2014, 129(6): 27-29.Fagius J and Burman J. (). Normal outcome of pregnancy with ongoing treatment with natalizumab. Acta Neurologica Scandinavica, 2014, 129(6): 27-29.Coyle P. Management of women with multiple sclerosis through pregnancy and after childbirth. Therapeutic Advances in Neurological Disorders, 2016, 9(3): 198-210.Coyle P. Management of women with multiple sclerosis through pregnancy and after childbirth. Therapeutic Advances in Neurological Disorders, 2016, 9(3): 198-210.Cohen J, Coles A, Arnold D, Confavreux C, Fox E, Hartung H, Havrdova E, Selmaj K, Weiner H, Fisher E, Brinar V, Giovannoni G, Stojanovic M, Ertik B, Lake S, Margolin D, Panzara M and Compston D. (). Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. The Lancet, 2012, 380(9856): 1819-1828.Cohen J, Coles A, Arnold D, Confavreux C, Fox E, Hartung H, Havrdova E, Selmaj K, Weiner H, Fisher E, Brinar V, Giovannoni G, Stojanovic M, Ertik B, Lake S, Margolin D, Panzara M and Compston D. (). Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. The Lancet, 2012, 380(9856): 1819-1828.

The authors declare that there are no conflicts of interest present.